Endometriosis Multi-Omics Map Reveals Systemic Links
Imagine a condition where cells that should stay inside the uterus grow outside it. They form lesions. They cause pain. They cause fatigue. They cause infertility. For decades, doctors thought of endometriosis as a local problem. The problem was in the pelvis. The problem was about tissue in the wrong place. The problem was driven by the hormone oestrogen. Treatments focused on hormones. They suppressed oestrogen. They shrank lesions. They relieved pain for some. But the condition did not stay local. It had effects far beyond the pelvis. Women with endometriosis had higher rates of cardiovascular disease. They had higher rates of arthritis. They had higher rates of depression. The biological link between the lesions and these distant effects remained a mystery.
A new study changes the picture. Researchers led by Shefali Setia-Verma at the University of Pennsylvania took a different approach. [1] They did not just look at genes. They did not just look at proteins. They did not just look at the microbiome. They combined all these layers of data. They called this a “multi-omics” approach. They built a holistic view of the condition. They analyzed data from 14 global biobanks. Together, these biobanks held information about more than a million women. This is the largest study of its kind for endometriosis.
The study identified 58 areas of the genome associated with endometriosis, 27 of which were previously unrecognized. [1]. A deeper analysis pinpointed 314 genes linked to the development of the condition. Many of these genes were involved in the immune system. Many were involved in inflammation. Many were involved in cell movement. The last of these is particularly important. Endometriosis involves cells growing where they should not. The study suggests the condition may not simply be about tissue in the wrong location. It may be about the biological process that allows cells to move. “That is really interesting, because we may be able to find treatments that target that movement,” says Setia-Verma. [1]
What Earlier Studies Got Wrong
Earlier studies of endometriosis had a major blind spot. They focused almost exclusively on populations of European ancestry. This limited how much the findings could be generalized. It contributed to broader disparities in women’s health research. Women of African ancestry were underrepresented. Women of Asian ancestry were underrepresented. Women of Indigenous ancestry were underrepresented. The new study corrects this gap. It is the first to identify specific genes linked to endometriosis in people of African ancestry. The study uncovered three genetic regions associated with endometriosis that were detected only by analyzing the genomes of people with African ancestry. This is a significant correction. It means that some genetic risk factors for endometriosis are ancestry-specific. It means that treatments developed from studies of European populations may not work equally for everyone.
Earlier studies also focused on hormonal pathways. Oestrogen makes lesions grow. Oestrogen makes lesions bleed. Oestrogen makes lesions inflame surrounding tissues. Treatments that suppress oestrogen can shrink lesions. They can relieve pain. But they do not address the systemic effects of the condition. They do not explain why endometriosis is linked to cardiovascular disease. They do not explain why it is linked to arthritis. They do not explain why it is linked to depression. The new study suggests that inflammation is a key driver. It suggests that the immune system is involved. It suggests that cell movement is involved. These are pathways that hormonal treatments do not target.
The Inflammation Connection
The links with inflammation and the immune system may explain why endometriosis can have effects beyond the lesions themselves. In some people, the condition may involve systemic inflammation that goes untreated for years. Setia-Verma points to the UK as an example. In the UK, it takes more than nine years, on average, to receive a diagnosis. “Those years of untreated pain and inflammation can lead to many long-term conditions,” she says. This is a critical insight. It means that the damage from endometriosis is not just from the lesions. It is from the chronic inflammation that the lesions cause. It is from the immune system being constantly activated. It is from the body being in a state of low-grade inflammation for years.
The study identified genes and proteins linked with endometriosis and cardiovascular disease. It also identified genes and proteins linked with the regulation of cholesterol and fats in the blood. “It’s essentially saying that endometriosis may be associated with a higher risk for cardiovascular conditions,” says Setia-Verma. This is a bridge between two fields. Cardiologists and gynaecologists have not traditionally worked together. This study suggests they should. It suggests that a woman with endometriosis may need to be monitored for cardiovascular risk. It suggests that treating the inflammation of endometriosis may reduce the risk of heart disease.
The Gut Microbiome Connection
Another intriguing finding involved the gut microbiome. People with endometriosis tend to have lower levels of Bifidobacteriaceae. These are bacteria involved in maintaining the gut lining. They support the immune system. “It gives us an understanding of how endometriosis contributes to broader systemic disease risk beyond reproductive health,” says Setia-Verma. This is a new piece of the puzzle. The gut microbiome is known to influence inflammation throughout the body. It is known to influence the immune system. It is known to influence mood. If endometriosis alters the gut microbiome, it could explain some of the systemic effects. It could explain the depression. It could explain the fatigue. It could explain the arthritis.
Microbiologists can now look more closely at the role Bifidobacteriaceae bacteria play in the condition. They can potentially use it as a target for new treatments. Probiotics that boost Bifidobacteriaceae could be tested. Diet changes that support these bacteria could be tested. This is a completely new avenue for endometriosis research. It moves beyond the pelvis. It moves beyond hormones. It moves into the gut.
What This Study Corrects
The study corrects several earlier assumptions. First, it corrects the assumption that endometriosis is only a pelvic condition. It shows that the condition has systemic effects. It shows that inflammation is a key driver. It shows that the immune system is involved. It shows that cell movement is involved. Second, it corrects the assumption that genetic studies of European populations are sufficient. It shows that ancestry-specific genetic factors exist. It shows that research must include diverse populations. Third, it corrects the assumption that hormonal treatments are the only option. It suggests that targeting inflammatory pathways with existing drugs could be effective. It suggests that targeting cell movement could be effective. It suggests that targeting the gut microbiome could be effective.
The study also corrects the assumption that endometriosis is a single disease. The 314 genes identified suggest that there may be different subtypes. Some may be driven more by inflammation. Some may be driven more by cell movement. Some may be driven more by hormonal factors. This could explain why some women respond to hormonal treatments and others do not. It could explain why some women have severe pain and others have mild symptoms. It could explain why some women develop cardiovascular disease and others do not.
What Remains to Be Corrected
Nilufer Rahmioglu at the University of Oxford points out what remains to be done. [2] “While studies of this type can identify biological pathways and traits that warrant further investigation, they do not by themselves establish that targeting these pathways will improve outcomes for patients. Further replications are needed.” [2] This is a crucial caveat. The study identifies targets. It does not prove that hitting those targets will work. The 314 genes need to be studied in detail. The 27 new genomic areas need to be confirmed. The three ancestry-specific genetic regions need to be replicated in larger African ancestry populations.
The study also does not explain why endometriosis develops in the first place. It does not explain why some women get it and others do not. It does not explain why the tissue grows outside the uterus. It does not explain why the immune system does not clear the lesions. These questions remain. They are the next frontier.
The Door That Just Opened
The study opens several doors. The first door is treatment. Existing drugs that target inflammatory pathways could be tested for endometriosis. These drugs are already approved for other conditions. They are already known to be safe. They could be repurposed quickly. The second door is diagnosis. The 314 genes could be used to develop a diagnostic test. A blood test could identify women at risk. A blood test could diagnose the condition earlier. This could reduce the nine-year delay in diagnosis. This could prevent years of untreated pain and inflammation.
The third door is personalized medicine. The different subtypes of endometriosis could be treated differently. A woman whose condition is driven by inflammation could get anti-inflammatory drugs. A woman whose condition is driven by cell movement could get drugs that block cell movement. A woman whose condition is driven by hormonal factors could get hormonal treatments. This is the promise of precision medicine.
The fourth door is prevention. The gut microbiome finding suggests that diet and lifestyle could play a role. Boosting Bifidobacteriaceae through diet could reduce inflammation. It could reduce the risk of developing endometriosis. It could reduce the severity of symptoms. This is a low-cost, low-risk intervention. It could be implemented now.
The fifth door is collaboration. The study brings together geneticists, immunologists, microbiologists, and clinicians. It brings together researchers from different countries. It brings together data from different biobanks. This collaborative approach is the model for future research. It is the only way to understand a condition as complex as endometriosis.
The Next Scientific Question
The study answers many questions. It raises one big question. The question is: Can we stop the movement? The study identified genes involved in cell movement. Endometriosis involves cells growing where they should not. The cells must move to get there. They must travel from the uterus to other parts of the body. They must implant. They must grow. If we can stop the movement, we can stop the condition. We can prevent lesions from forming. We can prevent pain. We can prevent inflammation. We can prevent the systemic effects.
This is the door that just opened. The study provides the map. It shows the genes. It shows the proteins. It shows the pathways. The next step is to find the key. The key is a drug that blocks cell movement. The key is a drug that targets the immune system. The key is a drug that reduces inflammation. The key is a probiotic that restores the gut microbiome. The key is a diagnostic test that catches the condition early.
The study corrects decades of assumptions, neglect, and underrepresentation, opening a new chapter focused on understanding endometriosis as a systemic condition, treating it as a whole-body disease, and preventing it before it starts.
Shefali Setia-Verma and her colleagues have provided the foundation; the next steps depend on researchers, clinicians, and the women who have been waiting for answers. The answers are coming, and the door is open.